@anetoc Profile picture

Abel Costa, MD

@anetoc

Hematologist. Tweets are my own.

Similar User
Wellington Fernandes photo

@wellingtonhemat

Fabio Pires photo

@fabiopss

Mariana Guarana photo

@mariana_guarana

Lucas Cantadori photo

@lucascantadori

Phillip Scheinberg photo

@scheinbp

Isabela photo

@isaisabelagap

Guilherme Perini, MD photo

@GuiperiniMD

Eduardo F O Ribeiro photo

@EduardoFlavioO1

Fernanda Santos photo

@fernandahemato

Renato Cunha, M.D.-Ph.D. photo

@DrRenatoCunha

Gabriel Cortopassi photo

@Cortopassi_GM

Chaitra Ujjani, MD photo

@UjjaniC

The Fellow On Call photo

@TheFellowOnCall

Abel Costa, MD Reposted

#Myeloma Paper of the Day: Brazilian study of real-life experience of myeloma (MMyBRAve) finds improvement in outcomes (median OS in transplantation-ineligible and eligible patients of 49 & 93 months), but remaining diagnostic and therapeutic gaps: pubmed.ncbi.nlm.nih.gov/39488485/. #mmsm

Tweet Image 1
Tweet Image 2
Tweet Image 3
Tweet Image 4

Abel Costa, MD Reposted

Salles et al 5 yr results of POLARIX 1L RCT PolaRCHP vs RCHOP in IPI 2-5 DLBCL 5-year PFS estimates 64.2% vs 59.1% HR 0.78; 95% CI: 0.623-0.980 5-year OS 82.2% vs 79.6% not significant #ASH2024 #lymsm

Tweet Image 1

Abel Costa, MD Reposted

CONGRESS | #IMS2024 | PRESENTATION Abel Costa @anetoc shares findings from a trial of sonrotoclax + dexamethasone in patients with RRMM harboring t(11;14) mutations (N=32). The ORR was 75% among 24 efficacy-evaluable patients, with a ≥ VGPR of 50%. The combination was well…

Tweet Image 1
Tweet Image 2
Tweet Image 3
Tweet Image 4

Abel Costa, MD Reposted

R/R T-ALL. Therapeutic approach. - How I treat, blood journal 2023. - ESMO guidelines 2024. - ELNetwork guidelines 2024. - NCCN guidelines 2024. What is the best scheme before the alloSCT (antiCD38, Bortezomib, VEN…) ?

Tweet Image 1
Tweet Image 2
Tweet Image 3
Tweet Image 4

Abel Costa, MD Reposted

Great presentation by Suzanne Lentzsch on Linvoeltamab on RRMM - ORR 71% ,CRS 46%, and a high PFS (70%) at 12mos - need to see if this holds up - ? Best in class or selection bias- too early to tell

Tweet Image 1

Abel Costa, MD Reposted

Next generation CAR with novel binding domain! Deep and durable response in high risk patients! Look forward to getting this to our patients! ⁦@MCWCancerCenter⁩ ⁦@EHA_Hematology#eha2024

Tweet Image 1
Tweet Image 2
Tweet Image 3

Abel Costa, MD Reposted

Guideline paradigms in EMD @JHillengass at #IMWG2024. @Myeloma_Society #mmsm

Tweet Image 1

Check out our poster at #EHA2024 with safety and efficacy data from the Ph 1/2 study with Golcadomide +/- Ritux for R/R FL @GuiperiniMD

Tweet Image 1
Tweet Image 2

Starting an intense week of activities in Madrid. Very Excited for #EHA24

Tweet Image 1

Abel Costa, MD Reposted

Results GHSG HD21 BrECADD v eBEACOPP in 1L cHL #ASCO24: - 1500 pts, med age 31, Stage IIB 17%, rest adv stage - PFS superior in BrE arm: 4 yr 94% vs 91% (!!!) - less tox & neuropathy with BrE - 96% gonadal recovery with BrE (73% with escB) New standard of care in cHL? #lymsm

Tweet Image 1

Abel Costa, MD Reposted

First of the @NEJM #ASCO24 myeloma papers that I will be highlighting. Congrats @dra_v_hungria @mvmateos @thanosdimop et al. nejm.org/doi/full/10.10…

Tweet Image 1

Abel Costa, MD Reposted

Interested to see EPCORE-CLL1 update: epcoritamab for Richter's transformation, now n=35 - ORR 50%, CR 35% - higher in treatment-naive subgroup - promising signal for a difficult-to-treat disease - combinations likely the way forward here #lymSM #EHA24 library.ehaweb.org/eha/2024/eha20…

Tweet Image 1

Abel Costa, MD Reposted

Classic Hodgkin Lymphoma in Adolescents and Young Adults: on line and in print @JCO_ASCO Enjoyed working on this with @KaraKellyMD ascopubs.org/doi/full/10.12…


Abel Costa, MD Reposted

How I manage bone modifying agents (BMAs) in #myeloma to avoid jaw osteonecrosis: #mmsm - Obtain dental eval before starting BMAs - If pending invasive dental procedure, advise holding BMAs 2-3 months before and after - Dental exams every 6 months Ref: mdpi.com/2072-6694/13/1…

Tweet Image 1

Amazing results for older HL! #ASH2023

Rutherford et al - BV-AVD v N-AVD in older Hodgkin - SWOG 1836 study, 60y+, n=103 (approx 50 each arm) - med age 66, more high risk in N-AVD - Less tox with N-AVD: GI, PN, sepsis - 1y PFS 64v93% - 1y OS 83v95% (not stat signif) - NRM 4v14% A game changer. #ASH23 #lymsm

Tweet Image 1
Tweet Image 2
Tweet Image 3
Tweet Image 4


Abel Costa, MD Reposted

T-cell lymphoma. Flow Cytometry approach. Key points.

Tweet Image 1

Abel Costa, MD Reposted

The total mass, number, & distribution of immune cells in the human body | PNAS pnas.org/doi/full/10.10…

Tweet Image 1

Abel Costa, MD Reposted

"The existence of two acute myeloid leukaemia classification systems...is concerning... and threatens the ability to... deliver appropriate... management strategies" NEW Viewpoint—Standardising acute myeloid leukaemia classification systems #leusm thelancet.com/journals/lanha…

Tweet Image 1

Abel Costa, MD Reposted

#Glofitamab approved in Europe for r/r DLBCL. The CD20×CD3 bispecifics are the most potent single drugs so far tested in this indication, I hope they will be made available #lymsm globenewswire.com/news-release/2…


Abel Costa, MD Reposted

A collection of clincally important insights in myeloma and MGUS. #MedTwitter 1/ Serum protein electrophoresis may underestimate the true size of the M protein when the level is too high. The gel saturates. So go by the quantitative IgG/IgA level to get a better estimate of M…


Loading...

Something went wrong.


Something went wrong.